Treadwell Therapeutics

Treadwell Therapeutics

  • Founded: 2019
  • Location: New York, NY
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: AML, MDS, CMML
  • Drug types: ONC
  • Lead product: CFI-400945
  • Product link:
  • Funding: $27M seed Jan 2020

job board

Short description:

Oncology Small Molecules

Drug notes:

Also 5 additional trials Clin1 multiple cancers; CFI-402257 Clin1 breast cancer, 2 additional trials Clin1 breast cancer, solid tumors; CFI-402411 Clin1 solid tumors; undisclosed programs RD/Clin0 multiple cancers

Long description:

Treadwell Therapeutics is developing novel therapeutics to treat highly aggressive cancers. Building upon work uncovered from their scientific co-founders, Treadwell is focused on drug discovery and development to identify promising targets and programs to treat cancer. This involves the combination of RNAi screens, cell surface protein screens, knockout mice technology and their human B-cell mining platform to identify tumor vulnerabilities. Treadwell’s pipeline includes therapeutics for multiple targets as well as various modalities, including small molecules and T cell therapies. Their lead program, TWT-202, is a small molecule that has entered clinical trials for AML patients.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy